Lyell Immunopharma, Inc. — Director's Dealing 2021

Jun 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2021-06-21

Reporting Person: Klausner Richard (Director, Executive Chairman)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-21	Common Stock	C	3765842	—	Acquired	3765842	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-21	Series A Convertible Preferred Stock	$	C	3765842	Disposed		Common Stock (3765842)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2967834	Direct

Footnotes

F1: The Issuer's Series A Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date.

F2: The Reporting Person is a manager of Lyell Investors, LLC
(Lyell Investors) and may be deemed to share the power to direct the disposition and vote of the shares held by Lyell Investors. The Reporting
Person disclaims beneficial ownership of all shares held by Lyell Investors except to any pecuniary interest therein